Page 55 - Solid Tumors News Today

Global GLP-1 Receptor Agonists Market 2021 Key Indicators – GSK, Haosoh, Novo Nordisk, Lily, AstraZeneca, Sanofi davidMay 3, 2021 12 Global GLP-1 Receptor Agonists Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 introduced from Marketquest.biz offers users excellent business intelligence for the organization of different sizes. Our report is a unique blend of multidisciplinary approaches taken by our experts to cover all edges by deploying real-time big data a...

- PRESERVE 2 Will Evaluate Survival Benefit of COSELA in 250 Patients with Locally Advanced Unresectable or Metastatic TNBC - RESEARCH TRIANGLE PARK,...

Share this article Share this article DUBLIN, April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy. The study will evaluate intravenously administered (IV) nemvaleukin in patients with mucosal melanoma and subcutaneously administere...

Share this article Share this article SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) solid tumors that fail to respond to the standard therapy, has been accepted by the National Medical Products Administration (NMPA) and proposed to be granted priorit...

Published: Apr 19, 2021   BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020. "2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, w...

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent 1 A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer Merck is leading more than ten clinical trials across DNA Damage Response (DDR) pathways in various tumor types Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investig...

Share this article Share this article INDIANAPOLIS, April 11, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo ® (selpercatinib) demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 Ame...

Search jobs 09-Apr-2021 Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer - FDA Action Date is October 10, 2021 - - BLA Submission Supported by Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 - BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--...

Search jobs 09-Apr-2021  Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer FDA action date is Oct 10, 2021 BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)-- Genmab A...

Search jobs 08-Apr-2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update Preliminary Phase 1b Data - Gedatolisib showed a potentially differentiated safety and tolerability profile - Corporate Update - Proceeds from first $15 million tranche increase cash-on-hand to $44 million - - Drug development capabilities ...